0.29
+0.0448(+18.07%)
Currency In USD
| Previous Close | 0.25 |
| Open | 0.29 |
| Day High | 0.32 |
| Day Low | 0.26 |
| 52-Week High | 15.64 |
| 52-Week Low | 0.22 |
| Volume | 38.7M |
| Average Volume | 830,922 |
| Market Cap | 697,243 |
| PE | 0.02 |
| EPS | 17.17 |
| Moving Average 50 Days | 1.49 |
| Moving Average 200 Days | 1.85 |
| Change | 0.03 |
If you invested $1000 in GRI Bio, Inc. (GRI) since IPO date, it would be worth $0 as of December 30, 2025 at a share price of $0.248. Whereas If you bought $1000 worth of GRI Bio, Inc. (GRI) shares 3 years ago, it would be worth $0.02 as of December 30, 2025 at a share price of $0.248.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GRI Bio Announces Closing of $8.0 Million Public Offering
GlobeNewswire Inc.
Dec 12, 2025 9:05 PM GMT
LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrot
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
GlobeNewswire Inc.
Dec 11, 2025 2:15 PM GMT
LA JOLLA, CA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrot
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire Inc.
Dec 10, 2025 9:05 PM GMT
Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used with existing approved treatments Study met its sec